INTRODUCTION
============

The nuclear envelope (NE) defines the boundary between the nucleus and the cytoplasm ([@B36]; [@B13]). The nucleoplasmic face of the NE is lined by the nuclear lamina, a dense protein interface connecting the inner nuclear membrane and chromatin ([@B56]; [@B13]). Major structural constituents of the lamina are the intermediate filament proteins lamins A and C, encoded by the *LMNA* gene ([@B17]). The A-type lamins are ubiquitously expressed in most adult somatic cells and assemble into higher-order filaments. Together with the B-type lamins, expressed from separate genes, lamin complexes contribute to nuclear structure and influence nuclear organization ([@B13]).

Although the most-studied functional aspects of A-type lamins are the structural roles they play during interphase, lamins A/C are increasingly recognized as mediators, and possibly regulators, of diverse nuclear processes ([@B23]). They are implicated in higher-order genome organization, since they physically interact with chromatin, and cells deficient for lamins A/C show a loss of peripheral heterochromatin, ectopic chromatin condensation, and mispositioning of centromeric heterochromatin ([@B60]; [@B57]; [@B41]; [@B18]; [@B6]). Lamins A/C may also play a role in DNA repair as cells expressing mutant forms of lamin A exhibit a delay in recruitment of repair factors to sites of DNA damage and show increased levels of double-strand breaks ([@B35]; [@B38]). Lamins A/C have also been linked to signal transduction pathways involved in differentiation and homeostasis by regulating the activity and availability of proteins within the mitogen-activated protein kinase-- and RB-cell cycle pathways ([@B23]). They are also implicated in transcription and DNA replication, possibly by aiding assembly of the transcription and replication machineries ([@B32]; [@B55]; [@B69]).

Many of these activities rely on lamin A/C--protein interactions. Lamins A/C associate with B-type lamins and homopolymerize ([@B67]). In addition to lamin--lamin interactions, lamins bind to proteins anchored in the inner nuclear membrane, such as thymopoietin (TMPO; LAP2) or emerin ([@B69]). Together with SUN1 and nesprins, lamins form the LINC (linkers of the nucleoskeleton to the cytoskeleton) complex, which physically connects the nuclear membrane and lamina to the cytoskeleton ([@B10]). Lamins A/C also interact with nucleoplasmic proteins such as barrier-to-autointegration factor (BAF), which prevents viral integration, and chromatin remodeling complexes, including the nucleosome remodeling and histone deacetylation component retinoblastoma-binding protein 4 ([@B39]; [@B42]). In some cases, interaction with nucleoplasmic proteins serves to sequester proteins to the nuclear periphery, thus reducing the nucleoplasmic concentration. For example, lamin A physically interacts with the transcription factor Fos and retains it at the nuclear lamina, leading to suppression of activating protein-1--dependent transcription ([@B27]; [@B22]).

Mutations in the *LMNA* gene cause a heterogeneous set of human diseases. More than 300 *LMNA* mutations have been identified and causally linked to \>15 distinct diseases, which are referred to as laminopathies ([@B59]; [@B13]). The laminopathic disease mutations are distributed throughout the *LMNA* gene and show little correlation to disease type ([@B59]; [@B13]). A prominent hallmark of laminopathies is their high tissue specificity. Among the laminopathies, Emery--Dreifuss muscular dystrophy (EDMD), limb girdle muscular dystrophy 1B (LGMD1B), and dilated cardiomyopathy 1A (CMD1A) primarily affect muscle, whereas Dunnigan-type familiar partial lipodystrophy (FPLD) affects adipose tissue, and Charcot--Marie--Tooth neuropathy 2B1 (CMT2B1) impairs function of the peripheral nervous system ([@B45]; [@B64]). A second class of laminopathies involves multiple tissues in different combinations, such as mandibuloacral dysplasia with type A lipodystrophy (MADA) and Hutchinson--Gilford progeria syndrome (HGPS; [@B45]; [@B64]).

How mutations in *LMNA* cause disease and why many laminopathies are highly tissue specific are unclear and particularly intriguing, given that lamins A/C are expressed in most adult tissues ([@B47]). One model for the tissue specificity of laminopathies proposes that variants of lamins A/C may affect interactions with proteins that are themselves expressed in a tissue-specific manner ([@B51]). In support, nuclear envelope proteomes are highly variable among tissues ([@B29]). However, connecting altered lamin A/C protein interactions to clinically relevant molecular mechanisms remains a challenge.

To gain insights into the pathological mechanisms involved in laminopathies, we sought to systematically identify lamin A--interacting proteins whose binding is affected by disease-linked mutations. We screened an unbiased human ORFeome library comprising \>12,000 genes to identify lamin A/C--binding proteins and probed their interaction with a comprehensive panel of 89 disease-linked lamin A variants. Our screening efforts identified novel lamin A/C-interacting proteins whose interaction is disrupted by laminopathy disease mutations, revealed lamin A/C residues important for protein--protein interactions, and identified disease-specific lamin A interactions at multidisease mutation sites. Our results support the notion that the tissue specificity of laminopathies is strongly driven by loss of tissue-specific lamin A/C interactions.

RESULTS
=======

Systematic identification of lamin A--interacting proteins
----------------------------------------------------------

To identify lamin A--interacting proteins in an unbiased manner, we performed a yeast two-hybrid (Y2H) screen using the human ORFeome V5.1 library, which contains 15,483 cloned open reading frames (ORFs), corresponding to 12,794 nonredundant human genes (a complete list of ORFs is available at <http://horfdb.dfci.harvard.edu/hv5/>). The library represents a comprehensive collection of ORFs and provides higher coverage than traditional Y2H libraries, the composition of which is limited by the gene expression pattern of the source tissue or cells from which the cDNA library is prepared, a potentially limiting factor when attempting to identify tissue-specific lamin A interactors ([@B4]; [@B37]). The ORFeome library also ensures equal representation of each gene, in contrast to traditional Y2H libraries, in which the abundance of each clone in the library reflects its endogenous expression level. Because each ORFeome construct is sequence verified, the rate of false positives due to out-of-frame clones and mutations is minimized.

Each ORFeome clone was introduced into two Y2H expression vectors to generate a complete library of protein fusions between the ORF and Gal4 DNA--binding domain (DB-Y) and the Gal4 activation domain (AD-Y; [@B33]). Conversely, 41 unique lamin A fragments (Supplemental Table S1A), all of varying size and encoding different combinations of lamin A domains, were introduced into Y2H expression vectors to generate protein fusions with the Gal4 activation domain (AD-lamin A) or the Gal4 DNA--binding domain (DB-lamin A). The use of multiple lamin A fragments increases the throughput of candidate protein identification and ameliorates potential cytotoxic effects. DB and AD constructs were transformed into the haploid *Saccharomyces cerevisiae* strains Y8930 (*MAT*α) and Y8800 (*MAT*a), respectively, and two complementary screening strategies were performed ([Figure 1A](#F1){ref-type="fig"}; [@B15]). In a "forward" screen, 85 plates, each containing a different pool of 188 AD-ORFeome constructs, were tested against individual DB-lamin A constructs arrayed on a single plate ([Figure 1A](#F1){ref-type="fig"}). In a "reverse" screen, the 41 AD-lamin A constructs were pooled and tested against individual DB-ORFeome constructs, which were arrayed across 147 plates ([Figure 1A](#F1){ref-type="fig"}). Each screen was performed twice, and putative interactors were identified based on growth on selective media (see *Materials and Methods*; [@B15]). As a control, yeast were replica plated onto media containing cycloheximide, which counterselects for the AD vector and aids in identifying DB-Y autoactivating proteins ([@B15]). Approximately 1.2 million protein--protein combinations were tested, and positive yeast colonies were cultured and replated on selective and control media for secondary phenotyping. Only colonies that continued to grow on selective media, and not on control media, were considered primary hits. The identity of the primary hits was verified by yeast colony PCR amplification of the insert and end-read sequencing.

![Yeast two-hybrid screen design and results. (A) Schematic of primary screen strategy. In the forward screen, 188 *MATα* yeast, each transformed with a unique AD-Y construct (where Y is an ORFeome clone), are pooled, and an aliquot is deposited into 85 96-well plates. *MATa* yeast, each transformed with a unique DB-lamin A construct (41 in total), are also deposited in 96-well plates such that each well contains a unique DB-lamin A construct. Yeast are then mated in liquid YEPD medium (188 × 1). In the reverse screen, 41 *MATα* yeast, each transformed with a unique AD-lamin A construct, are pooled and deposited into 96-well plates. *MATa* yeast, each transformed with a unique DB-Y construct, are deposited into 147 96-well plates so that each well contains a unique DB-Y construct. Yeast are then mated in liquid YEPD medium (41 × 1). After the mating reaction, yeast are plated in duplicate on SC/-Leu/-Trp/-His +1 mM 3-AT to select for interactors and SC/-Leu/-His, +1 mM 3-AT +1 mg/L cycloheximide (CHX) to select for autoactivators. Primary positive colonies are consolidated into 96-well plates containing liquid SC/-Leu/-Trp media, cultured overnight, and then replated on selection plates for secondary phenotyping. Colony PCR was performed for each primary positive, and the results were sequenced. Each screen was repeated twice and identified 623 unique interactors. (B) Schematic of the retest strategy. Fresh archival stocks of 426 unique primary positives are retested against pools of AD/DB-lamin A. Of these, 337 retested positive and are considered verified interactors. (C) Venn diagram of the retest results. Of the primary positives, 49% from the forward screen retested and 83% of the primary positives in the reverse screen retested. Primary positives identified in both screens (forward or reverse) retested at higher rates than those only identified in a single screen.](1493fig1){#F1}

Overall 623 unique interactors were identified in the four screens ([Figure 1A](#F1){ref-type="fig"} and Supplemental Table S2). As expected, the forward screen was less sensitive (∼50 hits/replica) compared with the reverse screen (∼420 hits/replica) due to decreased sampling, with more constructs screened per well in the forward screen (188 AD-ORFeome constructs vs. 41 AD-lamin A constructs). In addition, reporter sensitivity is lower in the forward screen because DB-lamin A acts as a transcriptional repressor when tethered to the *GAL4* promoter ([@B34]). Of the 623 primary positives identified, 426 were retested in the Y2H assay with fresh archival stocks of the ORFeome library, resulting in 337 (79%) validated interactors ([Figure 1, B and C](#F1){ref-type="fig"}, and Supplemental Table S1, C and D; see *Materials and Methods*). Four interactors (CCDC120, CMTM5, LMNA, and TRIM39) were identified in all four screens, and six interactors (AGTRAP, ARL6IP1, PIK3R2, SCARA3, STX4, and TOR1AIP1) were identified in three of the four screens and all validated in retests. We identified 333 interactors in two of four screens, and of 281 of these interactors 258 (∼92%) validated. Two hundred eighty interactors were identified in only one of four screens, and of 135 of these, 69 (∼51%) validated in retesting. Thirteen of the identified interactors, including LMNA, LMNB1, LMNB2, TMPO, and PCNA, had previously been reported as lamin A--interacting proteins, confirming the quality of the screening approach ([@B53]).

A subset of interactors was chosen randomly for biochemical validation in pull-down assays using N-terminally yellow fluorescent protein (YFP)-tagged interactors expressed in U2OS cell lines that stably express OneStrepTag-lamin A fusion (OST-lamin A) or OneStrepTag alone (OST; [Figure 2](#F2){ref-type="fig"}; [@B31]). Twelve of 18 Y2H interactors were detectable in pull-down assays, which included known lamin A interactors such as LMNA itself, TMPO, and LMNB1, in addition to several of the novel lamin A interactors ([Figure 2](#F2){ref-type="fig"}). These results demonstrate that the interaction data set is enriched for lamin A--interacting proteins.

![Validation of Y2H-verified interactors by pull-down assay. Validation of lamin A interactors in U2OS cells that stably express OneStrepTag-lamin A fusion (OST-Lamin A) or, as a negative control, OneStrepTag alone (OST). The U2OS cells were transfected with YFP fusions to the indicated proteins. Pulled-down proteins were detected using anti-GFP.](1493fig2){#F2}

Cellular localization of interactors
------------------------------------

Given that lamin A accumulates prominently at the nuclear periphery, we tested the localization of a subset of 104 interactors by high-throughout microscopy after expression in U2OS cells of N-terminally YFP-tagged versions of the interactors ([Figure 3](#F3){ref-type="fig"} and Supplemental Table S2). The localization pattern of each candidate was visually scored and categorized according to the extent of NE accumulation and cellular localization ([Figure 3A](#F3){ref-type="fig"}). Several known lamin A interactors were included in the visual screen, such as LMNA, LMNB1, LMNB2, and TMPO, which served as positive controls for NE accumulation, and untagged YFP alone, which served as a negative control. We found that 53% of interactors showed NE accumulation ([Figure 3B](#F3){ref-type="fig"}) and 47% of interactors did not accumulate at the NE but were homogeneously distributed throughout the nucleus and/or cytoplasm ([Figure 3B](#F3){ref-type="fig"}). Note that peripheral localization is not a prerequisite for lamin interactors, as lamin A is also present in the nuclear interior, and several bona fide lamin interactors are diffusely distributed throughout the nucleus ([@B25]; [@B14]). Of the interactors that accumulated at the NE, 17% were exclusively nuclear, whereas the remaining candidates localized to the nucleus and cytoplasm. Of the interactors that did not accumulate at the NE, only 8% were exclusively localized in the cytoplasm. ([Figure 3B](#F3){ref-type="fig"}).

![Localization of verified interactors. (A) Visual screen scoring for nuclear envelope accumulation. Each candidate was scored as strong to medium (blue), weak (red), or no (green) accumulation at the NE. (B) Localization pattern for lamin A interactors with respect to nuclear envelope accumulation and cellular localization (cyto, exclusively cytoplasmic; nuc, exclusively nuclear; nuc/cyto, both nuclear and cytoplasmic localization). (C) Localization pattern for progerin-specific interactors with respect to nuclear envelope accumulation and cellular localization.](1493fig3){#F3}

Identification of progerin-specific interactors
-----------------------------------------------

To apply the ORFeome screening strategy to a specific laminopathy, we analyzed the Y2H interactome of progerin, the lamin A isoform responsible for the premature aging syndrome HGPS ([@B16]). Progerin is a dominant lamin A isoform generated by the G608G mutation, which activates an intronic alternative pre-mRNA splice site ([@B16]). Owing to the activation of the internal splice site, progerin has a 50--amino acid deletion in the C-terminal tail, which leads to its permanent farnesylation ([@B20]). Five progerin constructs of varying length were tested in the primary screen, and the resulting validated candidates were classified according to their interaction with lamin A and/or progerin (Supplemental Table S1C; see *Materials and Methods*). We identified 225 progerin-specific interactions, 51 proteins that interacted with both lamin A and progerin (Supplemental Table S1D), and 61 interactors that were specific to lamin A. Of 80 progerin-specific interactors tested for their cellular localization, 89% displayed NE staining ([Figure 3C](#F3){ref-type="fig"}), compared with only 53% of lamin A ([Figure 3B](#F3){ref-type="fig"}). Of interest, only 8% of progerin-specific interactors, which accumulated at the NE, were also localized exclusively in the nucleus, in contrast to 17% of lamin A--specific or lamin A/progerin interactors ([Figure 3, B and C](#F3){ref-type="fig"}).

Gene Ontology (GO) analysis confirmed the notion that progerin-specific interactors are a distinct group of proteins from lamin A interactors. Whereas lamin A interactors were enriched for components of the NE and lamina ([Figure 4A](#F4){ref-type="fig"}; *p* \< 1 × 10^^−^3^), progerin-specific interactors comprised mostly integral and intrinsic membrane proteins and components of the endoplasmic reticulum (ER; [Figure 4B](#F4){ref-type="fig"}; *p* \< 1 × 10^^−^3^). The progerin-specific interactors were enriched for proteins with soluble *N*-ethylmaleimide--sensitive factor attachment protein receptor activity and channel and transmembrane transporter activity ([Figure 4B](#F4){ref-type="fig"}; *p* \< 1 × 10^^−^3^). Progerin-specific interactors were also enriched for proteins that function in vesicle-mediated transport, membrane organization, transmembrane transport, and establishment of protein localization ([Figure 4B](#F4){ref-type="fig"}; *p* \< 1 × 10^^−^3^). The higher percentage of progerin-specific interactors that displayed NE staining compared with lamin A interactors might be explained by the preponderance of membrane-related components in this group, as high levels of membrane proteins might aggregate in the ER, which is continuous with the NE.

![GO analysis. (A) Lamin A--interacting candidates and (B) progerin-specific candidates were analyzed for the GO categories cellular components (CC), biological process (BP), and molecular function (MF) against the ORFeome library as background. GO terms significantly enriched (*p* \< 1 × 10^^−^3^) over background are listed next to the number of candidates annotated with the GO term over the total number of annotated candidates in each category.](1493fig4){#F4}

The observation that a higher percentage of progerin-specific interactors are not exclusively found in the nucleus but are also in the cytoplasm suggests that interactions may reflect pre--lamin A processing, which is thought to take place, in part, in the cytoplasm ([@B2]). A key step in the maturation of lamin A is the addition and eventual removal of a C-terminal farnesyl group ([@B63]), whereas progerin is permanently farnesylated ([@B20]). To test for a potential role of farnesylation in the identified interactions, we probed progerin interactors against several lamin A variants impaired in farnesyl processing ([Table 1](#T1){ref-type="table"}). Of 223 progerin-specific candidates tested, none maintained its interaction with a progerin fragment containing a C661S mutation, which blocks transfer of the farnesyl moiety onto the terminal cysteine in lamin A or progerin ([Table 1](#T1){ref-type="table"}; [@B7]). The effect of the C661S variant was specific to the progerin-only interactors and did not globally disrupt all interactions with progerin, since of the 27 candidates that interacted both with progerin and lamin A, 9 (33%) maintained their interaction with progerin C661S ([Table 1](#T1){ref-type="table"}). Conversely, of 220 progerin-specific interactors tested, 165 (75%) gained interaction with lamin A L647R, a variant that causes permanent farnesylation by blocking cleavage of the farnesyl group by the lamin A endoprotease ZMPSTE24 ([@B43]; [@B9]; [@B20]). These observations demonstrate that the majority of progerin interactions are mediated by its farnesylated C-terminus and that protein farnesylation is sufficient to mediate lamin A--protein interactions.

###### 

Role of farnesylation in interactions.

                       **DB-verified interactors**        **DB-verified interactors**         
  -------------------- ----------------------------- ---- ----------------------------- ----- ----
  Lamin A              0                             27   Lamin A                       0     22
  Progerin             223                           27   Progerin                      220   22
  Lamin A Cys661Ser    1                             17   Lamin A Lys647Arg             165   22
  Progerin Cys661Ser   0                             9                                        

Two groups of DB-interactors were tested against AD-lamin A and AD-progerin constructs containing mutations affecting farnesylation. Numbers indicate how many DB-interactors interacted with each AD-lamin A or AD-progerin construct. Progerin-specific interactors only interact with farnesylated progerin. None of the 223 progerin-specific interactors interacted with AD-progerin Cys661Ser, a progerin variant that prevents farnesylation. Conversely, farnesylation of lamin A is sufficient to gain interaction with progerin-specific interactors. Of 220 progerin-specific interactors, 165 gained interaction with the lamin A Lys647Arg variant, which causes permanent farnesylation.

Systematic identification of interactors involved in laminopathies
------------------------------------------------------------------

Next we sought to identify disease-relevant interactors more broadly by testing a subset of 58 interactors, chosen based on their ability to interact robustly with multiple lamin A fragments, against a panel of 89 lamin A variants that represent 15 known laminopathies and are distributed throughout the lamin A protein ([Figure 5](#F5){ref-type="fig"} and Supplemental Table S3). We used the Y2H assay to test 4918 unique interactor--lamin A mutant binary pairs and identified 554 pairings that resulted in a loss of interaction ([Figure 5](#F5){ref-type="fig"} and Supplemental Table S3). The number of lost interactions among lamin A mutants ranged from 0 (0/42) to 75% (43/57; [Figure 6](#F6){ref-type="fig"}; see later discussion).

![Variant test summary heat map. Heat map summary of lamin A variant tests. The *y*-axis, laminopathy variants (*n* = 89); *x*-axis, interactors (*n* = 58). Green indicates no effect on interaction, red indicates a lost interaction, yellow indicates conflicting results between different lamin A fragments, and white indicates that no test was performed.](1493fig5){#F5}

![Percentage lost interactions, by lamin A variant. Bars represent the percentage of lost interactions for each variant. Variants are ordered numerically along the *x*-axis.](1493fig6){#F6}

Four of the lamin A mutants did not lose interaction with any of their binding partners. One of them, Arg377His, is located within the α-helical coiled coil 2B domain and is implicated in limb girdle muscular dystrophy D1, Emery--Dreifuss muscular dystrophy 2, and dilated cardiomyopathy 1A, whereas the remaining three, Asp136His, Glu145Lys, and Glu159Lys, are located within the α-helical coiled-coil 1B domain and are associated with HGPS ([@B40]; [@B16]; [@B52]; [@B46]; [@B19]). Together with Ser143Phe, a fourth HGPS-associated lamin A variant, HGPS variants within the coiled-coil 1B domain had only a minimal effect, losing interaction with 2.5% of candidates compared with 17% for the rest of the variants in the coiled-coil 1B domain. The tendency of HGPS-associated variants to have little or no effect on protein--protein interactions supports a model in which disturbed assembly of lamin filaments, which leads to dominant gain-of-function effects, is the cause of HGPS ([@B21]; [@B11]). The effects of the HGPS-associated variants probably manifest as perturbations in higher-order filament formation, since none of the variants prevented lamin dimer formation (Supplemental Table S3).

Structure--function interaction analysis
----------------------------------------

The availability of a comprehensive library of lamin A mutants allowed mapping of the lamin A protein domains required for interactions. Of note, lamin A variants inside the immunoglobulin (Ig)-like fold domain lost interaction with more candidates than variants in the unstructured C-terminal tail ([Table 2](#T2){ref-type="table"}). The Ig-like fold domain is composed of two β-sheets that are closely associated in a β-sandwich ([@B12]; [@B30]). The side chains of some residues orient toward the core of the domain and participate in stabilization of the β-sandwich through hydrophobic contacts and hydrogen bonds ([@B12]; [@B30]). As expected, the most severely affected Ig-like domain mutants are two core variants, Leu454Pro and Asn456Lys, which lost interaction with 72 and 75% of candidates tested, respectively ([Table 3](#T3){ref-type="table"}). The third most severely affected Ig-like domain mutant was Arg455Pro, which lost interaction with 40% of candidates ([Table 3](#T3){ref-type="table"}). Unlike the side chains of Leu454 and Asn456, which are both positioned within the core of the Ig-like fold, a structural role of Arg455 has not been determined. The large effect of the Arg455Pro variant suggests that like Leu454 and Asn456, the side chain of Arg455 is oriented within the core and important for the stability of the Ig-like fold domain. Asn456Ile lost interaction with 18% of candidates, whereas Asn456Asp lost interaction with only 1% of candidates. The different effects for various Asn456 variants are likely a reflection of how the core domain accommodates the structural differences between amino acid side chains.

###### 

Summary of lost interactions, by lamin A/C protein domain.

  **Lamin A/C protein domain**                **Variant tests**   **Lost interactions**   **Average lost interactions (%)**
  ------------------------------------------- ------------------- ----------------------- -----------------------------------
  Coiled coil 1B                              273                 34                      12
  L12 linker                                  21                  4                       19
  Coiled coil 2A                              18                  1                       6
  Coiled coil 2B                              367                 32                      9
  Tail (before nuclear localization signal)   268                 11                      4
  Tail (nuclear localization signal)          73                  4                       5
  Ig-like fold                                2991                410                     14
  Core residues                               1461                290                     20
  Solvent-exposed residues                    534                 31                      6
  Residue position not determined             996                 89                      9
  Tail (after Ig-like fold)                   907                 58                      6
                                              **Total = 4918**    **Total = 554**         **Average = 11**

Buried side chains predicted to be positioned within the core of the Ig-like fold domain: Val440Met, Leu454Pro, Asn456Asp, Asn456Ile, Asn456Lys, Trp467Arg, Ile469Thr, Arg471Cys, Arg471Gly, Arg471His, Tyr481His, Leu512Pro, Trp520Gly, Trp520Ser, Thr528Met, Thr528Lys, Thr528Arg, Leu530Pro, Arg541Cys, Arg541Ser, Arg541Gly, Arg541His, and Arg541Pro. Residues predicted to be solvent exposed in the Ig-like fold domain: Arg453Trp, Arg482Trp, Arg482Gln, Arg482Leu, Lys486Asn, Arg527Cys, Arg527His, and Arg527Pro.

###### 

Summary of variant panel test, by lamin A variant. Continued

                                                                  **Lamin A 2--664**   **Lamin A 259--664**   **Lamin A 388--664**   **Total**                                                                     
  ----------------------- --------------------------------------- -------------------- ---------------------- ---------------------- ----------- -------- --------- -------- ------- ---------- --------- -------- ----
  **Coiled coil 1B**      **273**                                 **34**               **12**                                                                                        **273**    **34**    **12**   
  Arg89Cys                EDMD2                                   21                   3                      14                                                                                21        3        14
  Arg89Leu                CMD1A                                   21                   3                      14                                                                                21        3        14
  Arg133Pro               EDMD2                                   21                   3                      14                                                                                21        3        14
  Arg133Leu               WS, FPLD2, lipoatrophy syndrome         21                   1                      5                                                                                 21        1        5
  Asp136His               HGPS                                    21                   0                      0                                                                                 21        0        0
  Leu140Arg               WS                                      21                   11                     52                                                                                21        11       52
  Ser143Pro               CMD1A                                   21                   3                      14                                                                                21        3        14
  Ser143Phe               EDMD2, HGPS                             21                   2                      10                                                                                21        2        10
  Glu145Lys               HGPS                                    21                   0                      0                                                                                 21        0        0
  Thr150Pro               EDMD2                                   21                   3                      14                                                                                21        3        14
  Glu159Lys               HGPS                                    21                   0                      0                                                                                 21        0        0
  Glu161Lys               CMD1A, DCM-CD                           21                   1                      5                                                                                 21        1        5
  Asp192Gly               CMD1A, DCM-CD                           21                   4                      19                                                                                21        4        19
  **L12 linker**          **21**                                  **4**                **19**                                                                                        **21**     **4**     **19**   
  His222Pro               EDMD2                                   21                   4                      19                                                                                21        4        19
  **Coiled coil 2A**      **18**                                  **1**                **6**                                                                                         **18**     **1**     **6**    
  Arg249Gln               EDMD2, LGMD1B                           18                   1                      6                                                                                 18        1        6
  **Coiled coil 2B**      **126**                                 **21**               **17**                 **241**                **11**      **5**                               **367**    **32**    **9**    
  Tyr267Cys               EDMD2, CMD1A                            21                   2                      10                     7           0        0                                     28        2        7
  Arg298Cys               CMT2B1                                  21                   10                     48                     39          2        5                                     60        12       20
  Glu317Lys               CMD1A                                   21                   3                      14                     39          3        8                                     60        6        10
  Glu358Lys               EDMD2, CMD, dropped head syndrome       18                   2                      11                     39          4        10                                    57        6        11
  Arg377His               LGMD1B, CMD1A, EDMD2,                   3                    0                      0                      39          0        0                                     42        0        0
  Arg377Leu               LGMD1B, AD-SMA, CMD1A, MD               21                   2                      10                     39          0        0                                     60        2        3
  Arg386Met               EDMD2                                   21                   2                      10                     39          2        5                                     60        4        7
  **Tail (before NLS)**   **84**                                  **8**                **10**                 **106**                **3**       **3**    **78**    **0**    **0**   **268**    **11**    **4**    
  Ser395Leu               Metabolic syndrome                      18                   1                      6                      7           0        0         13       0       0          38        1        3
  Gln396Arg               EDMD2                                   21                   2                      10                     7           0        0         13       0       0          41        2        5
  Arg399Cys               FPLD2, CMD1A                            21                   1                      5                      7           0        0         13       0       0          41        1        2
  Arg399His               Metabolic syndrome                      21                   3                      14                     7           2        29        13       0       0          41        5        12
  Arg401Cys               EDMD2                                                                                                      39          1        3         13       0       0          52        1        2
  Val415Ile               LAF                                     3                    1                      33                     39          0        0         13       0       0          55        1        2
  **NLS**                 **21**                                  **2**                **10**                 **39**                 **2**       **5**    **13**    **0**    **0**   **73**     **4**     **5**    
  Leu421Pro               Metabolic syndrome                      21                   2                      10                     39          2        5         13       0       0          73        4        5
  **Ig-like domain**      **927**                                 **156**              **17**                 **1531**               **248**     **16**   **533**   **6**    **1**   **2991**   **410**   **14**   
  Arg435Cys               HGPS, RD                                21                   13                     62                     39          1        3         13       0       0          73        14       19
  Arg439Cys               FPLD2, metabolic syndrome               21                   1                      5                      39          0        0         13       0       0          73        1        1
  Val440Met               CMD1A                                   21                   2                      10                     39          1        3         13       0       0          73        3        4
  Asp446Val               EDMD2                                   21                   1                      5                      39          1        3         13       0       0          73        2        3
  Gly449Asp               EDMD2                                   21                   0                      0                      39          6        15        13       0       0          73        6        8
  Arg453Trp               EDMD2, LGMD1B                           3                    1                      33                     39          7        18        13       0       0          55        8        15
  Leu454Pro               EDMD2                                   21                   13                     62                     39          30       77                                    60        43       72
  Arg455Pro               Dropped head syndrome                   21                   7                      33                     39          17       44                                    60        24       40
  Asn456Asp               Dropped head syndrome                   18                   1                      6                      39          0        0         13       0       0          70        1        1
  Asn456Ile               EDMD2                                   21                   6                      29                                                    13       0       0          34        6        18
  Asn456Lys               EDMD2                                   18                   14                     78                     39          29       74                                    57        43       75
  Gly465Asp               FPLD2                                   21                   3                      14                     39          0        0         13       1       8          73        4        5
  Trp467Arg               EDMD2                                   21                   7                      33                     39          7        18        13       0       0          73        14       19
  Ile469Thr               EDMD2                                   21                   2                      10                     39          0        0         13       0       0          73        2        3
  Arg471Cys               HGPS, MADA, RSS                         21                   1                      5                      7           0        0         13       0       0          41        1        2
  Arg471Gly               FPLD2, FPLD1                            21                   1                      5                      39          0        0         13       0       0          73        1        1
  Arg471His               CMD1A                                   21                   2                      10                     7           3        43        13       0       0          41        5        12
  Tyr481His               LGMD1B                                  21                   3                      14                     7           0        0         13       0       0          41        3        7
  Arg482Trp               FPLD2                                   21                   2                      10                     39          1        3         13       0       0          73        3        4
  Arg482Gln               FPLD2                                   21                   2                      10                     39          0        0         13       0       0          73        2        3
  Arg482Leu               FPLD2                                   21                   3                      14                     39          1        3         13       0       0          73        4        5
  Lys486Asn               FPLD2                                   21                   3                      14                     39          0        0         13       0       0          73        3        4
  Thr488Pro               LAF                                     21                   2                      10                     39          2        5         13       0       0          73        4        5
  Trp498Arg               EDMD2, CMD1A                            21                   2                      10                     7           2        29                                    28        4        14
  Trp498Cys               LGMD1B                                  21                   2                      10                     39          4        10        13       0       0          73        6        8
  His506Asp               Metabolic syndrome                      18                   3                      17                     39          0        0         13       0       0          70        3        4
  Leu512Pro               LGMD1B                                  21                   2                      10                     39          1        3         13       0       0          73        3        4
  Trp520Gly               EDMD2                                   21                   2                      10                     39          22       56        13       1       8          73        25       34
  Trp520Ser               EDMD2                                   21                   3                      14                     39          21       54        13       1       8          73        25       34
  Gly523Arg               CMD1A                                   21                   2                      10                     39          2        5         13       0       0          73        4        5
  Arg527Cys               HGPS, MADA                              21                   2                      10                     39          5        13        13       0       0          73        7        10
  Arg527His               MADA                                    21                   2                      10                     39          0        0         13       0       0          73        2        3
  Arg527Pro               EDMD2, CMD1A, EDMD3                     21                   2                      10                     7           0        0         13       0       0          41        2        5
  Thr528Met               HGPS, FPLD1                             18                   13                     72                     39          2        5         13       0       0          70        15       21
  Thr528Lys               EDMD2, LGMD1B                           21                   3                      14                     39          23       59        13       0       0          73        26       36
  Thr528Arg               EDMD2                                   21                   3                      14                     39          21       54        13       0       0          73        24       33
  Ala529Thr               MADA                                    18                   2                      11                     7           0        0         13       0       0          38        2        5
  Ala529Val               MADA                                    21                   4                      19                     39          0        0         13       0       0          73        4        5
  Leu530Pro               EDMD2                                   21                   2                      10                     7           0        0                                     28        2        7
  Arg541Cys               CMD1A, cardiac arrhythmia               21                   0                      0                      39          1        3         13       0       0          73        1        1
  Arg541Ser               CMD1A, EDMD2                            21                   9                      43                     39          2        5         13       1       8          73        12       16
  Arg541Gly               CMD1A                                   18                   0                      0                      39          5        13        13       1       8          70        6        9
  Arg541His               EDMD2                                   21                   2                      10                     39          3        8         13       1       8          73        6        8
  Arg541Pro               EDMD2, MD                               21                   2                      10                     39          21       54        13       0       0          73        23       32
  Lys542Asn               HGPS                                    18                   2                      11                     39          4        10        13       0       0          70        6        9
  Arg545Cys               EDMD2                                   21                   2                      10                     39          3        8         13       0       0          73        5        7
  **Tail**                **243**                                 **30**               **12**                 **482**                **24**      **5**    **182**   **4**    **2**   **907**    **58**    **6**    
  Ser573Leu               CMD1A, LGMD1B, FPLD2                    21                   2                      10                     39          0        0         13       0       0          73        2        3
  Glu578Val               HGPS                                    18                   1                      6                      7           0        0         13       0       0          38        1        3
  Arg582His               FPLD2                                   18                   2                      11                     39          0        0         13       0       0          70        2        3
  Ser583Leu               FPLD1                                   21                   1                      5                      39          0        0         13       0       0          73        1        1
  Arg584His               FPLD2                                   21                   1                      5                      39          1        3         13       0       0          73        2        3
  Cys588Arg               HGPS                                    18                   1                      6                      39          7        18        13       1       8          70        9        13
  Cys591Phe               FPLD2                                   21                   5                      24                     39          6        15        13       0       0          73        11       15
  Gly602Ser               Type A insulin resistance syndrome      21                   9                      43                     39          0        0         13       0       0          73        9        12
  Gly608Ser               HGPS                                    21                   3                      14                     39          0        0         13       0       0          73        3        4
  Thr623Ser               HGPS                                    18                   2                      11                     39          4        10        13       0       0          70        6        9
  Arg624His               EDMD2                                   3                    0                      0                      39          2        5         13       1       8          55        3        5
  Gly635Asp               CMD1A                                   18                   1                      6                      7           0        0         13       0       0          38        1        3
  Arg644Cys               CMD1A, HGPS, EDMD2, FPLD2, neuropathy   21                   2                      10                     39          3        8         13       2       15         73        7        10
  Arg644His               CMD1A                                   3                    0                      0                      39          1        3         13       0       0          55        1        2
  **Grand total**         **1713**                                **256**              **15**                 **2399**               **288**     **12**   **806**   **10**   **1**   **4918**   **554**   **11**   

Results of lamin A variant panel tests according to variant. Variants are listed in ascending order, grouped by domain, and followed by the associated laminopathy. Variant panels were constructed in three different lamin A fragments: lamin A 2--664, lamin A 259--664, and lamin A 388--664. The number of validated interactors tested against each fragment for each variant is indicated, as well as the number that lost interaction. For a complete list see Supplemental Table S3. NLS, nuclear localization signal.

Side chains situated on the surface of the Ig-like fold domain, such as Trp482, are not predicted to affect the overall stability of the Ig-like fold domain, but are expected to affect protein--protein interactions ([@B12]). Three different Trp482 variants, Trp482Gln, Trp482Leu, and Trp482Trp, lost interaction with 4% of candidates ([Table 3](#T3){ref-type="table"}), which is comparable to the 6% average of all solvent-exposed residues ([Table 2](#T2){ref-type="table"}). Overall lamin A variants whose substitutions affect core residues involved in maintaining the β-structure lost interactions with on average 20% of the candidates, compared with 6% for 8 variants affecting solvent-exposed residues and 9% for 15 variants affecting residues without a determined orientation, in line with a critical global role of the β-sheet structure in mediating interactions of lamin A with its partners ([Table 2](#T2){ref-type="table"}).

The relationship between the number of lost interactions and the location of lamin A mutations within the Ig-like domain fits a previously noted correlation of disease type and location of lamin A mutations within the Ig-like domain ([@B12]). Our study included 23 variants that are predicted to affect the Ig-like domain core. Of these 21 are implicated in EDMD2, LGMD1B, CMD1A, and other types of muscular dystrophies and lose interaction with 20% of candidates. In comparison, of the eight variants in our study predicted to have surface-exposed residues, six cause FPLD2, HGPS, and MADA and lose interaction with only 6% of candidates. These results agree with the noted correlation between Ig-like fold structure and resulting diseases. Ig-like fold domain mutations associated with muscular dystrophies and cardiomyopathies generally affect core residues and disrupt overall protein stability, whereas mutations associated with lipodystrophies and progeria are surface-exposed residues and do not affect overall domain stability.

Interactors affected by laminopathy variants
--------------------------------------------

In a converse approach, we asked how many interactions each lamin A interactor lost when tested against the panel of 83 lamin A mutants ([Table 4](#T4){ref-type="table"}). Of the 58 interactors tested, 50 lost interaction with at least one mutant ([Table 4](#T4){ref-type="table"} and [Figure 7](#F7){ref-type="fig"}). The interaction of eight candidates with lamin A was insensitive to lamin A mutations. Of importance, this group includes lamins LMNA, LMNB1, and LMNB2, suggesting that none of the variants significantly impairs lamin dimer formation mediated through the central coiled-coil domain. The other lamin A interactions that were insensitive to mutation were proliferating cell nuclear antigen (PCNA), reticulon 1/3 (RTN1/3), CREB3, and SENP2, suggesting that these proteins contain multiple, redundant lamin A interaction sites or that the relevant lamin A mutants that affect their interaction is not present in the panel. For the 50 interactors that lost binding with lamin A mutants, the number per candidate ranged from 1 to 72% ([Table 4](#T4){ref-type="table"} and [Figure 7](#F7){ref-type="fig"}). Of note are the combined losses of TMPO, TOR1AIP1, and DUSP13, which shared 10 mutant variants with which they lost interaction. Remarkably, 9 of the 10 variants cause CMD1A or EDMD2, which are diagnosed as separate diseases but have overlapping symptoms. Mutations in TMPO are known to cause CMDT1A, a cardiomyopathy, whereas DUSP13 and TOR1AIP1 have not previously been implicated in any diseases. All three interactors likely play a role, given the significant overlap among the candidates, the known association of TMPO with cardiomyopathies, and the similarities between EDMD2 and cardiomyopathies.

![Percentage lost interactions, by lamin A interactor. Bars represent number of lost interactions as a percentage of all interactors tested for individual variants. Candidates are ranked according to their percentage of lost interactions.](1493fig7){#F7}

###### 

Summary of variant panel tests, by candidate. Continued

  **Fragment**    **Candidate**   **Variants introduced in fragment**   **Lost interactions**             **Interactions lost (%)**
  --------------- --------------- ------------------------------------- --------------------------------- ---------------------------
  LMNA 2--664                                                                                             
  AD              DB-                                                                                     
                  CCNG1           83                                    21                                25
                  DUSP13          83                                    19                                23
                  FAIM            83                                    7                                 8
                  LMNA            83                                    0                                 0
                  LMNB1           83                                    0                                 0
                  LMNB2           83                                    0                                 0
                  MORF4L1         83                                    41                                49
                  MTHFD2          83                                    12                                14
                  PNKP            83                                    4                                 5
                  TCEANC          83                                    7                                 8
                  TCEB3           83                                    8                                 10
                  TMEM199         83                                    1                                 1
                  TMPO            83                                    11                                13
                  TOR1AIP1        83                                    18                                22
                  ZNF3            83                                    60                                72
                  ZNF439          83                                    14                                17
                  ZNF440          83                                    14                                17
                  ZNF69           83                                    6                                 7
                  ***n* = 18**                                          **Total = 243, average = 13.5**   **Average = 16**
  DB              AD-                                                                                     
                  CCDC120         73                                    12                                16
                  LMNA            73                                    0                                 0
                  PIAS2           73                                    1                                 1
                  ***n* = 3**                                           **Total = 13, average = 4.3**     **Average = 6**
  LMNA 259--664                                                                                           
  AD              DB-                                                                                     
                  ABCA9           59                                    8                                 14
                  ANXA6           59                                    8                                 14
                  C12orf48        59                                    18                                31
                  C4orf6          59                                    13                                22
                  CENPP           59                                    20                                34
                  CETN3           59                                    8                                 14
                  DDX43           59                                    11                                19
                  FAM164C         59                                    3                                 5
                  FCER1A          59                                    7                                 12
                  GIN1            59                                    16                                27
                  MTHFD2          59                                    7                                 12
                  MYADM           59                                    9                                 15
                  PKD2            59                                    10                                17
                  RANBP9          59                                    8                                 14
                  RGS18           59                                    8                                 14
                  SEC22A          59                                    7                                 12
                  SENP2           59                                    0                                 0
                  SIAH1           118^a^                                23                                19
                  SLC30A8         59                                    5                                 8
                  SPANXC          59                                    9                                 15
                  SPANXD          59                                    7                                 12
                  STAC2           59                                    8                                 14
                  TCEANC          59                                    9                                 15
                  TCEB3           59                                    4                                 7
                  TM4SF20         59                                    11                                19
                  TMEM199         59                                    0                                 0
                  TMEM74          59                                    4                                 7
                  UBE2Q1          59                                    7                                 12
                  ZNF138          59                                    9                                 15
                  ZNF439          59                                    5                                 8
                  ZNF569          59                                    8                                 14
                  ***n* = 31**                                          **Total = 270, average = 8.7**    **Average = 14**
  DB              AD-                                                                                     
                  ARL6IP1         73                                    4                                 5
                  CCDC120         73                                    4                                 5
                  CCDC155         73                                    2                                 3
                  IFFO1           73                                    2                                 3
                  KPNA6           73                                    3                                 4
                  PCNA            73                                    0                                 0
                  RTN4            73                                    3                                 4
                  ***n* = 7**                                           **Total = 18, average = 2.6**     **Average = 4**
  LMNA 388--664                                                                                           
  DB              AD-                                                                                     
                  AGTRAP          62                                    2                                 3
                  ARL6IP1         62                                    0                                 0
                  C20orf141       62                                    2                                 3
                  CCDC155         62                                    0                                 0
                  CREB3           248^a^                                0                                 0
                  DERL1           62                                    6                                 10
                  PCNA            62                                    0                                 0
                  RTN1            62                                    0                                 0
                  RTN3            62                                    0                                 0
                  RTN4            62                                    0                                 0
                  ***n* = 10**                                          **Total = 10, average = 1**       **Average = 2**
                                  **Total = 4918**                      **Total = 554**                   

Results of lamin A variant panel tests according to candidate. The Fragment column indicates which AD/DB-lamin A fragment fusion protein interacts with the corresponding AD/DB-candidate fusion. In the third column, the number of disease-associated variants introduced in each lamin A fragment is indicated, followed by the number of variants that caused a loss of interaction. The overall percentage of lost interactions per candidate is indicated in the last column.

^a^Combined results from multiple candidate isoforms.

Disease-specific interactions at multidisease mutation sites
------------------------------------------------------------

A remarkable feature of laminopathies is that phenotypically vastly distinct, tissue-specific diseases can be caused by differential amino acid substitutions of the same residue. A prominent example is Thr-528. Patients with Thr528Lys or Thr528Arg mutations suffer from muscular dystrophies, whereas Thr528Met causes progeria and a lipodystrophy as compound heterozygote with different lamin A variants ([@B5]; [@B44]; [@B62]; [@B49]; [@B61]; [@B3]; [@B68]; [@B50]; [@B48]). To test whether emergence of distinct diseases is related to loss of interaction with distinct sets of proteins, we tested lamin A isoforms with the three Thr-528 substitutions against a panel of 57 interactors. We identified 35 interactors that lost binding with at least one of the Thr-528 variants (Supplemental Table S3). Remarkably, the candidates largely grouped by disease ([Figure 8](#F8){ref-type="fig"}). Nineteen of the interactors lost association with the variants causing muscular dystrophies---Thr528Arg and Thr528Lys---but their interaction with Thr528Met, which causes HGPS and a lipodystrophy, was not affected. Conversely, 11 proteins lost interaction with the Thr528Met variant but not the Thr528Arg or Thr528Lys variants. The differential interaction properties correlate with the steric orientation of the mutant amino acids. The side chain of Thr-528 forms part of the core of the Ig-like fold domain, and substitutions, particularly with positively charged amino acids such as Arg and Lys, are predicted to disrupt folding and possibly reduce protein stability. In contrast, methionine, which is neutral and hydrophobic, more closely resembles threonine and is less likely to cause major structural changes.

![Disease-specific interactions at Thr-528 variants. Venn diagram of 35 candidates that lost interaction with Thr-528 variants. Nineteen of the candidates lost interaction only with Thr528Arg and Thr528Lys, which cause muscular dystrophies. Eleven of the candidates lost interaction with only Thr528Met, which causes HGPS and lipodystrophy.](1493fig8){#F8}

Additional multidisease mutations exist in *LMNA*. Patients with Arg133Pro mutations develop EDMD2, and those with Arg133Leu mutations develop Werner syndrome (WS) or lipodystrophies. We identified two interactors, DUSP13 and TMPO, that specifically lost interaction with Arg133Pro but not Arg133Leu. Another multidisease mutation site is Arg541. Arg541His and Arg541Pro mutations cause EDMD2, whereas Arg541Cys, Arg541Ser and Arg541Gly primarily cause CMD1A. We identified one candidate, MTHFD2, that lost interaction with Arg541 variants associated with EDMD2 but maintained interaction with variants associated with CMD1A. We conclude that variants at multidisease sites that cause related diseases show specificity for interaction partners, possibly explaining the tissue specificity of their appearance.

DISCUSSION
==========

Mutations in lamins and other proteins of the nuclear lamina have been linked to diverse pathologies ranging from muscular dystrophies to lipodystrophies, neuropathies, and progeroid aging syndromes ([@B45]; [@B64]). Although lamins A/C are widely expressed in most adult tissues, many of these diseases exhibit pronounced tissue specificity. It has been proposed that disrupted lamin A interactions with unidentified tissue-specific factors may mediate the development and tissue preferences observed in these diseases ([@B51]). This model is in line with the observed high degree of tissue specificity of the NE proteome ([@B29]). To unravel the pathogenic mechanisms in laminopathies, we screened an unbiased ORFeome library to identify lamin A interactors and systematically evaluated their interaction with 89 different lamin A disease variants.

We identified and validated 337 proteins that interact with lamin A or progerin. Reassuringly, the lamin A interactors included many known interactors, were significantly enriched for components of the lamina, NE, and NE membrane, and preferentially localized to the nuclear periphery. The high validation rate in orthogonal pull-down assays suggests that our set of candidates contains a significant number of genuine lamin A interactors. Comparison of the Y2H candidates with available NE proteomic data sets obtained from muscle and liver tissues and blood leukocytes indicated that of the 337 candidates, 35% are also found in NE biochemical fractions ([@B29]). It is important to note that the characterization of the NE proteome is incomplete and is variable across different tissue and cell types. Only 16% of NE proteins overlap between muscle, liver, and leukocytes, suggesting that the actual overlap between our candidates and the NE proteome is higher ([@B29]).

We identified 102 lamin A interactors, several of which are associated with at least one of the laminopathies or related diseases. These include LMNB2, which is associated with an acquired lipodystrophy, and TMPO, 2-actin, phospholamban, transmembrane protein 43 (TMEM43/LUMA), and vesicle-associated membrane protein 1/synaptobrevin 1, which are implicated in cardiomyopathies and other heart diseases. Whereas LMNB2 maintained its interaction with all lamin A variants, TMPO lost interaction with 11 variants, 9 of which cause cardiomyopathies or muscular dystrophies. It will be important to investigate the involvement of TMPO in cardiomyopathies caused by mutations in *LMNA*, particularly those identified here.

In addition, our approach has the potential to identify novel disease-relevant candidate proteins in an unbiased manner. One lamin A interactor, annexin VI (ANXA6), lost interaction with eight variants located within the Ig-like domain. Seven of the variants are buried within the core and cause EDMD2, whereas the orientation of the remaining variant is unknown and causes CMD1A. These findings dovetail with indications that ANXA6 may have a role in cardiomyopathies. Annexins are Ca^2+^ effectors that mediate cellular responses to changing intracellular levels of calcium, and elevated intracellular calcium concentrations cause the translocation of several annexins, including ANXA6, to the plasma membrane and nuclear envelope ([@B54]). Proteomic studies show that ANXA6 is a component of the NE in muscle, liver tissue, and blood cells ([@B29]). Overexpression of ANXA6 in cardiomyocytes of a transgenic mouse model causes hypertrophy and heart failure ([@B24]). During end-stage heart failure, levels of ANXA6 decrease in cardiomyocytes, whereas other annexins show increased levels ([@B28]). This has led to the view that down-regulation of ANXA6 during heart failure creates a framework that favors improved cardiomyoctye function ([@B24]). The involvement of ANXA6 in cardiomyopathies and muscular dystrophies warrants further study.

We tested 89 lamin A variants against 58 of the candidates that interact with lamin A, and we generated a comprehensive map of effects of variants on protein--protein interactions. This data set allowed us to understand which residues and protein domains are important for protein--protein interactions. Approximately half of the N-terminal portion of lamin A protein consists of coiled-coil domains. Mutations within the coiled-coil domains, including the linkers, lost interaction with on average 10% of candidates. The coiled-coil domain mediates dimerization with other lamins, but none of the lamins lost interaction with any of the variants, indicating that none of the variants participates in dimerization. The C-terminal half of lamin A, excluding the Ig-like domain, is unstructured and lost interaction with on average ∼6% of candidates. Except for a nuclear localization signal, the function of the unstructured domain is not well understood. Structural studies of the Ig-like domain indicate that residues whose side chains are oriented toward the core are crucial for stabilization of the β-sandwich ([@B12]; [@B30]). Consistent with the structural predictions, core variants lost interactions with on average 20% of candidates, compared with 6% of candidates for variants on the domain surface.

Systematic screening of known disease mutations has the potential to provide novel insights into disease mechanisms. The identification of a disproportionate number of progerin-specific interactors was unexpected, since only 5 of 41 lamin A constructs used in the primary screen contain the disease-relevant 50--amino acid deletion. The identification of gain-of-function progerin interactors is consistent with models of HGPS, which envision a dominant effect of progerin ([@B21]; [@B11]). Of interest, the 225 progerin-specific interactors were significantly enriched for membrane proteins, possibly reflecting a contribution of the C-terminal farnesyl group to their interactions. Conversely, 61 of 112 (54%) lamin A interactors lost interaction with progerin. Of the eight candidates that did not lose interaction with any of the missense lamin A variants, five lost interaction with progerin, including CREB3, PCNA, LMNB2, and two reticulons, RTN1 and RTN3. RTN4, a third reticulon, and ARL6IP1, a candidate that also contains the reticulon homology domain (RHD), also lost interaction with progerin. In variant tests with lamin A missense mutations, RTN4 and ARL6IP1 lost interactions with only 2 and 3% of candidates, respectively ([Figure 7](#F7){ref-type="fig"}), suggesting that the proteins containing the RHD are largely insensitive to laminopathy missense mutations but are sensitive to the deletion in progerin. Reticulons and ARL6IP1 have membrane-shaping activity, function as ER-shaping proteins ([@B66]; [@B65]), and also function in NE assembly by regulating the contribution of ER tubules to the nascent NE and in subsequent NE expansion ([@B1]). Nuclei from HGPS patients are lobulated and misshapen, which may indicate dysfunctional NE reformation and expansion.

Why different substitutions of the same lamin A residue cause vastly different diseases is an enigmatic feature of the laminopathies. In our Y2H analyses, multimutation residues that cause distinct diseases, such as Arg-133, Thr-528, and Arg-541, led to disease-specific loss of distinct sets of interactors. The results substantiate the genetics of laminopathy patients with molecular evidence, demonstrating that different substitutions of the same residue can have profoundly different effects on lamin A protein function. Identification of disease-specific candidates is a foothold for future functional studies and clinical efforts.

Lamin A/C is at the crossroads of many nuclear processes, and mutations cause a large number of diverse diseases. It is becoming increasing clear that the molecular functions of lamin A/C go far beyond its traditional role as a structural element and involve an extensive number of lamin A/C binding partners. Systematic identification of these interaction partners will provide the basis for the functional analysis of lamin A and its disease-causing mutants.

MATERIALS AND METHODS
=====================

Cloning, yeast transformations, and pool preparations
-----------------------------------------------------

Fragments of lamin A were amplified from cDNA using PfuUltra II Fusion HS DNA Polymerase (Agilent Technologies, Santa Clara, CA), cloned into the pDONR223 (Life Technologies, Carlsbad, CA) vector, and then verified by sequencing. See Supplemental Table S1A for a list of all lamin A fragments. pDONR223-lamin A fragments were then cloned into pAD/pDB vectors using LR Clonase II Plus enzyme (Life Technologies). Yeast strains Y8800 and Y8930 were transformed with pDB-lamin A and pAD-lamin A vectors, respectively, using a lithium acetate transformation protocol ([@B15]). An AD pool of 41 different pAD-lamin A fragment constructs transformed in Y8800 was constructed as described in [@B15]).

Yeast two-hybrid screen
-----------------------

Screening was performed essentially as described in [@B15]). Before the screen, the AD-/DB-lamin A constructs were tested to ensure that none of the fusion proteins were autoactivators. Glycerol yeast stocks of the DB-X (Y8930) or AD-pool (Y8800) strains were used to inoculate 96-well plates containing liquid selective media (SC/-Leu or SC/-Trp). Plates were incubated at 30ºC for 3 d with agitation. For the mating reaction, 5 μl of opposite-mating-type strains was combined in 96-well plates containing 160 μl of liquid yeast extract/peptone/dextrose (YEPD) per well and incubated overnight at 30ºC with shaking. A 5-μl amount of each mating reaction was replica plated onto SC/-Trp/-Leu/-His + 1 mM 3-amino-1,2,4-triazole (3-AT) media (screening plate) and SC/-Leu/-His + 1 mM 3-AT + 1 mg/l cycloheximide media (de novo autoactivator plate). Each set of plates was incubated at 30ºC for 3 d and scored for primary positives. Primary positives were defined as having a growth phenotype on the screening plate and a negative growth phenotype on the corresponding de novo autoactivator plate. Primary positive colonies were picked from the screening plate with sterile toothpicks and used to inoculate 96-well plates containing 160 μl of liquid SC/-Leu/-Trp media per well and then grown for 2 d at 30ºC. Then 5 μl of culture from the SC/-Leu/-Trp plate was spotted onto fresh selective agar medium plates and de novo activator plates to verify the primary positive phenotype (phenotyping II). After 3 d, plates were again scored for secondary positives, which were then used to inoculate 96-well plates containing 160 μl of fresh liquid SC/-Leu/-Trp media per well and grown for 2 d at 30ºC. Sequence identification of primary positives was performed by yeast colony PCR, followed by sequencing of the PCR product. To reduce false-positive rate and improve the quality of the interaction data set, primary positives were retested in the Y2H assay using fresh archival stocks of the ORFeome library. This archival library was prepared independently from the library used in the primary screen and helps to reduce the number of false positives caused by *cis*- or *trans*-acting mutations. Of the 623 primary positives in the primary screen, 426 (68%) were present in the retest. These primary positives were then tested against lamin A using a pooling strategy similar to that used in the primary screen, except that the 41 lamin A constructs were divided into six subpools in which each pool was assigned 5--11 lamin A constructs (note that 7 additional lamin A constructs not in the primary screen were included in the retest; see Supplemental Table S1, C and D, for composition of each pool and retest results). The six AD/DB-lamin A subpools were individually tested against the 426 AD/DB-ORFeome primary positive candidates ([Figure 1B](#F1){ref-type="fig"}). If the candidate scored positive with at least one of the six lamin A subpools, it was considered verified.

Transfections and pull-down assay
---------------------------------

U2OS cells stably expressing OneSTrEP-tagged lamin A (OST-lamin A) or the OneSTrEP epitope alone (OST; IBA, Goettingen, Germany) were grown until ∼90% confluence in 150-mm plates. Cells were transfected with YFP-candidate fusion constructs (pEYFP candidate) using GenJet reagent according to the manufacturer\'s instructions. After 24 h, cells were subjected to the pull-down procedure as previously described ([@B31]). We added 2× NuPAGE loading buffer (Life Technologies) to washed STrEPtactin matrix (IBA, Goettingen, Germany) and then heated it at 95˚C for 20 min to elute precipitated proteins.

GO analysis
-----------

GO analysis of interactors was performed for GO categories cellular components, biological process, and molecular function using ORFeome v5.1 (<http://horfdb.dfci.harvard.edu/hv5/>) as background ([@B26]). Entrez Gene IDs were used as input, and the default Database for Annotation, Visualization, and Integrated Discovery settings were used for analysis.

Western blot
------------

Samples were resolved on NuPAGE Bis-Tris Precast 4--12% gels (Life Technologies) and then blotted on polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA). Membranes were blocked for 1 h in blocking buffer (5% bovine serum albumin, 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Tween-20) and then incubated overnight at 4°C with anti-GFP antibody (Life Technologies) diluted 1:2000 with blocking buffer. The membranes were washed three times for 15 min with TBS-T (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Tween-20) and incubated with horseradish peroxidase--labeled anti-mouse (ECL mouse IgG; GE Healthcare, Little Chalfont, United Kingdom) diluted 1:5000 with blocking buffer for 1 h at room temperature and washed as before. Proteins were detected with Amersham ECL Plus Western Blotting reagent (GE Healthcare). Aliquots of pre--pull-down cell lysate for each sample were analyzed for levels of β-tubulin to ensure uniform protein levels.

Localization of candidates
--------------------------

The pEYFP-Y candidate constructs used in the visual screen were made by using available pAD/pDB-Y clones from the yeast ORFeome library. Yeast minipreps were performed using Zymoprep Yeast Plasmid Miniprep II (Zymo Research, Irvine, CA) according to the manufacturer\'s instructions. Rescued plasmids were transformed into TOP10-competent cells (Life Technologies), and candidate ORFs were amplified using miniprep DNA as template with PfuUltra II Fusion HS DNA Polymerase, using the forward primers AD (5′-CGCGTTTGGAATCACTACAGGG-3′) and DB (5′-GGCTTCAGTGGAGACTGATATGCCTC-3′), and the reverse primer Term (5′-GGAGACTTGACCAAACCTCTGGCG-3′). PCR products were recombined into a Gateway compatible pEYFP vector using LR Clonase II Plus enzyme (Life Technologies). Sequence-verified pEYFP constructs were transfected using GenJet In Vitro DNA Transfection Reagent (SignaGen Laboratories, Rockville, MD) into U2OS cells in 96-well clear-bottom microplates according to the manufacturer\'s instructions. Cells were fixed 48 h posttransfection with 4% paraformaldehyde in phosphate-buffered saline and stained with DRAQ5 (Cell Signaling Technology, Danvers, MA). Confocal fluorescence images of multiple fields from each well were captured using the CellVoyager CV6000 high-content microscopy system (Yokogawa Electric Corporation, Tokyo, Japan) and analyzed using ImageJ software (National Institutes of Health, Bethesda, MD).

Y2H lamin A--variant panel construction
---------------------------------------

A series of laminopathy variants was created in three fragments of lamin A: lamin A 2--664, lamin A 259--664, and lamin A 388--664. Mutations were introduced into fusion PCR products by site-directed mutagenesis (for a complete list of primers and variants see Supplemental Table S4), which were subsequently recombined into pDONR223 using BP Clonase and then verified by sequencing ([@B58]; [@B8]). This resulted in three variant panels: 1) pDONR223-lamin A 2--664 (*n* = 88 variants), 2) pDONR223-lamin A 259--664 (*n* = 73 variants), and 3) pDONR223-lamin A 388--664 (*n* = 62 variants). Collectively the three panels comprise 223 unique pDONR223-lamin A constructs and represent 89 unique laminopathy variants. The pDONR223-lamin A construct was then recombined into the Y2H vectors pAD and/or pDB using LR Clonase. This resulted in five variant panels: 1) pAD-lamin A 2--664 (*n* = 83 variants), 2) pAD-lamin A 259--664 (*n* = 59 variants), 3) pDB-lamin A 2--664 (*n* = 73 variants), 4) pDB-lamin A 259--664 (*n* = 73 variants), and 5) pDB-Lamin A 388--664 (*n* = 62 variants). All pAD-lamin A and pDB-lamin A constructs were used to transform haploid yeast strains Y8800 and Y8930, respectively, and are maintained as glycerol stocks.
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AD

:   activation domain

3-AT

:   3-amino-1, 2, 4-triazole

BP

:   biological process

CC

:   cellular components

CHX

:   cycloheximide

CMD1A

:   cardiomyopathy

CMT2B1

:   Charcot-Marie-Tooth neuropathy

cyto

:   cytoplasmic

DB

:   DNA-binding domain

EDMD

:   Emery-Dreifuss muscular dystrophy

ER

:   endoplasmic reticulum

FPLD

:   Dunnigan-type familiar partial lipodystrophy

GO

:   Gene Ontology

HPGS

:   Hutchinson-Gilford progeria syndrome

Ig

:   immunoglobulin

LAF

:   lone atrial fibrillation

LGMD1B

:   limb girdle muscular dystrophy

MADA

:   mandibuloacral dysplasia with type A lipodystrophy

MF

:   molecular function

NE

:   nuclear envelope

NLS

:   nuclear localization signal

nuc

:   nuclear

ORF

:   open reading frame

OST

:   OneStrepTag

RD

:   restrictive dermopathy

RSS

:   lamin-related rigid spine muscular dystrophy

YFP

:   yellow fluorescent protein

Y2H

:   yeast two hybrid
